Next Article in Journal
Co-Application of Milk Tea Waste and NPK Fertilizers to Improve Sandy Soil Biochemical Properties and Wheat Growth
Next Article in Special Issue
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth
Previous Article in Journal
Preparation and Utility of N-Alkynyl Azoles in Synthesis
Previous Article in Special Issue
Design, Synthesis, and Evaluation of Amphiphilic Cyclic and Linear Peptides Composed of Hydrophobic and Positively-Charged Amino Acids as Antibacterial Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 3
10.3390/molecules24030424
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Cyclic Peptide-Based Sirtuin Substrates

by
Di Chen
†,
Lingling Yan
† and
Weiping Zheng
*
School of Pharmacy, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2019, 24(3), 424; https://doi.org/10.3390/molecules24030424
Submission received: 19 December 2018 / Revised: 14 January 2019 / Accepted: 16 January 2019 / Published: 24 January 2019
(This article belongs to the Special Issue Peptides in Chemical Biology and Drug Discovery)
Browse Figures
Versions Notes

Abstract

:
In the current study, four side chain-to-side chain cyclic peptides (three 5-mers and one 4-mer) harboring Nε-acetyl-lysine or Nε-myristoyl-lysine were found to be in vitro substrates of the human SIRT1/2/3-catalyzed deacylation with good substrate activities, as judged by the kcat/KM ratios.

Graphical Abstract

1. Introduction

Sirtuins refer to a family of intracellular enzymes able to catalyze the β-nicotinamide adenine dinucleotide (β-NAD+)-dependent Nε-acyl-lysine deacylation on histone and non-histone proteins in organisms from all three evolutionary kingdoms of life (i.e., bacteria, archaea, and eukarya) [1,2,3,4,5,6,7,8]. Figure 1 depicts this enzymatic reaction in which the Nε-acyl-lysine substrate, β-NAD+, and water are converted to nicotinamide, deacylated product, and 2′-O-acyl-ADP ribose (2′-O-AADPR) [2,3,4,5,6,7]. The Nε-acyl specificity exhibited by the seven human sirtuins (i.e., SIRT1-7) is also shown in Figure 1 [2,3,4,5,6,7]. Specifically, while human SIRT1/2/3 are the three sirtuins that are able to proficiently catalyze the deacetylation of Nε-acetyl-lysine, they are also able to proficiently catalyze the demyristoylation of Nε-myristoyl-lysine; SIRT5 has strong Nε-malonyl/succinyl/glutaryl-lysine demalonylase/desuccinylase/deglutarylase activities; SIRT6 is a strong Nε-myristoyl-lysine demyristoylase; SIRT4 was very recently found to have strong Nε-glutaryl-lysine and Nε-3-methylglutaryl-lysine deacylase activities; and very recently, SIRT7 was found to be a Nε-succinyl-lysine desuccinylase. Moreover, SIRT7’s deacetylase and demyristoylase activities were found to be significantly enhanced by the presence of double-stranded DNA (dsDNA), ribosomal RNA (rRNA), and transfer RNA (tRNA).
The eukaryotic sirtuins including human sirtuins are found in nucleus, mitochondria, and cytosol [2,5,7,8]. In addition to histone proteins, the first identified eukaryotic sirtuin substrates, more and more non-histone substrates have also been found in the cellular compartments where sirtuins reside [2,5,7,8]. Therefore, it is not surprising that the sirtuin-catalyzed deacylation has been demonstrated to play an important regulatory role in multiple crucial cellular processes, e.g., transcription, metabolism, and DNA damage repair [2,5,9,10,11,12,13,14]. This enzymatic reaction has also been regarded as a novel therapeutic target for multiple human diseases such as cancer and the metabolic and neurodegenerative diseases [15,16,17,18]. Therefore, chemical modulators (inhibitors and activators) for the sirtuin-catalyzed deacylation have been actively pursued during the past few years [4,15,17,18,19], and quite a few in vitro sirtuin substrates have been developed and employed on in vitro screening platforms for such chemical modulators [20,21,22,23,24,25,26]. Given that the notable examples of the currently existing in vitro SIRT1/2/3 substrates 1–4, as shown in Figure 2, are all linear peptide-based, we envisioned that cyclic peptides could be superior substrates because cyclic peptides tend to have superior target binding affinity [27]. As a proof-of-concept endeavor, in the current study we prepared and assessed the SIRT1/2/3 substrate activities of cyclic peptides 5–8 shown in Figure 3. We found that, as judged by kcat/KM ratios, cyclic peptides 5, 7, and 8 were superior in vitro SIRT1 or SIRT3 substrates compared to the best linear hexapeptide-based in vitro SIRT1 or SIRT3 substrates reported in the current literature and shown in Figure 2.

2. Results and Discussion

2.1. Compound Design

It should be first noted that, in the current study the cyclic counterparts of the currently existing linear peptide-based SIRT1/2/3 substrates 1–4 were not pursued due to the need of an effort to determine the macrocycle bridging units that can be accommodated favorably at SIRT1/2/3 active sites; instead, we came up with the cyclic peptides 5–8 depicted in Figure 3 based on the following straightforward design.
Compounds I and II were found previously in our laboratory to be potent SIRT1/2/3 inhibitors [28]. While this strong inhibition could be derived from the use of the powerful catalytic mechanism-based SIRT1/2/3 inhibitory warhead Nε-thioacetyl-lysine [29,30] (the central residue in both compounds), it also suggested that the SIRT1/2/3 active sites were able to favorably accommodate the macrocycle bridging units in these two compounds which ought to be first recognized and processed by SIRT1/2/3 as substrates [29,30]. Therefore, we envisioned that simply replacing acetyl for thioacetyl in compounds I and II could afford robust SIRT1/2/3 substrates 5 and 6.
Since SIRT1/2/3 were also recently found to exhibit robust demyristoylase activity [26,31], it seemed plausible to construct another robust SIRT1/2/3 substrate by simply replacing the acetyl in compounds 5 and 6 with myristoyl, however, this replacement may result in a sub-optimal positioning of the macrocycle bridging units of 5 and 6 at SIRT1/2/3 active sites. Therefore, we opted to use the macrocyle bridging unit of compound III in Figure 3 that was found previously in our laboratory to also be a strong SIRT1/2/3 inhibitor [32]. Again, this observed strong inhibition could have resulted from the use of the depicted thiourea-type catalytic mechanism-based sirtuin inhibitory warhead [18] (i.e., the central lysine-derivatized residue); it also suggested that the SIRT1/2/3 active sites were able to favorably accommodate the specific macrocycle bridging unit in compound III that also ought to be first recognized and processed by SIRT1/2/3 as substrate [33]. Therefore, the macrocycle bridging unit of compound 7 is the same as that of compound III while the thiourea-type warhead in III was replaced with Nε-myristoyl-lysine in 7.

2.2. Compound Preparation

Compounds 5 and 6 were synthesized according to Scheme 1. Following the assembly and the N-term acetylation of the linear pentapeptide composed of Met, Lys(Mtt), Nε-acetyl-Lys, Lys(Boc), and Lys(Mtt) on the Rink amide resin based on the Nα-9-fluorenylmethoxycarbonyl (Fmoc) chemistry-based manual solid phase peptide synthesis (SPPS), the two side chain Mtt protecting groups were removed with 1% (v/v) trifluoroacetic acid (TFA)/N,N-dimethylformamide (DMF). For the synthesis of compound 5, the resulting peptidyl-resin with two exposed free amino groups was then reacted with Fmoc-Gly-OH followed by (i) Fmoc removal with 20% (v/v) piperidine/DMF and (ii) the subsequent reaction between the newly exposed two free amino groups on resin with suberic acid (2 equivalents) in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) (3.8 equivalents) and 0.4 M N-methylmorpholine (NMM)/DMF at room temperature for 1 h. For the synthesis of compound 6, the peptidyl-resin following Mtt removal was directly reacted with a di-acid (succinic acid, 2 equivalents) in the presence of HBTU (3.8 equivalents) and 0.4 M NMM/DMF at room temperature for 1 h. The above-described peptidyl resin obtained from the reaction with a di-acid (suberic acid or succinic acid) was then treated with a TFA-containing cocktail, affording the crude 5 or 6, which was purified with semi-preparative reversed-phase high performance liquid chromatography (RP-HPLC). The exact masses of the purified 5 and 6 were confirmed by high-resolution mass spectrometry (HRMS) analysis (Table 1). The purified 5 and 6 were each >95% pure based on a RP-HPLC analysis.
Scheme 2 depicts the synthesis of compound 7. Following the assembly and the N-term acetylation of the linear pentapeptide composed of Thr(tBu), Lys(Mtt), Lys(ivDde), Arg(Pbf), and Lys(Mtt) on the Rink amide resin based on the Fmoc chemistry-based manual SPPS, the two side chain Mtt protecting groups were removed with 1% (v/v) TFA/DMF. The resulting peptidyl-resin with two exposed free amino groups was then reacted with suberic acid (2 equivalents) in the presence of HBTU (3.8 equivalents) and 0.4 M NMM/DMF at room temperature for 1 h. The ivDde protecting group on the obtained peptidyl-resin was then selectively removed with 2% (v/v) hydrazine/DMF, and the newly exposed free amino group on the resin was subsequently reacted with myristic acid. The crude 7 was then cleaved from the resin with Reagent K (a TFA-containing cocktail) and purified by semi-preparative RP-HPLC. The exact mass of the purified 7 was confirmed by HRMS analysis (Table 1). The purified 7 was >95% pure based on a RP-HPLC analysis.
The 4-mer 8 was synthesized (see Scheme 3) in the same manner as the above-described synthesis of the 5-mer 5. The crude 8 was also purified with semi-preparative RP-HPLC and the exact mass of the purified 8 was also confirmed by HRMS analysis (Table 1). The purified 8 was also >95% pure based on a RP-HPLC analysis.2.3. Compound Evaluation with In Vitro SIRT1/2/3 Substrate Activity Assay
The steady-state kinetic parameters (kcat and KM) for the SIRT1/2/3 substrate activities of the purified 5–8 were determined with a HPLC-based sirtuin deacylation activity assay and are recorded in Table 2 and Table 3. As judged by kcat/KM ratios, cyclic peptides 5–8 were all found to be excellent SIRT1 substrates, actually 5, 7, and 8 are all better SIRT1 substrates than the linear hexapeptide-based SIRT1 substrate 3 (depicted in Figure 2) reported in the current literature (kcat/KM = 800 M−1 s−1) [22]. Cyclic peptides 5–8 were also all found to be better SIRT3 substrates than the linear hexapeptide-based SIRT3 substrate 3 reported in the current literature (kcat/KM = 990 M−1·s−1) [22]. Even though cyclic peptides 5–8 were found to be ~17-68-fold weaker SIRT2 substrates than the best SIRT2 substrate (i.e., 4 depicted in Figure 2) reported in the current literature (kcat/KM = 1.76 × 105 M−1·s−1) [23], this literature SIRT2 substrate was based on a linear nonapeptide.

2.3. Compound Evaluation with Pronase Digestion Assay

With compounds 5–7 in hand, we also performed a proteolysis experiment to assess the proteolytic stability of these three cyclic peptides. Pronase was employed in the experiment as the proteolytic enzyme preparation since pronase is composed of a variety of different types of proteases and peptidases, and thus, has a very broad substrate specificity [34]. As indicated in Figure 4, compounds 6 and 7 were found to be proteolytically much more stable than compound 5, while these three cyclic peptides are all proteolytically much more stable than the linear pentapeptide H2N-HK-(Nε-acetyl-lysine)-LM-COOH also employed in the proteolysis experiment. Given the relatively lower proteolytic stability of 5, we also set out to identify its stable proteolysis product(s) and found one such product via HRMS analysis, compound 5a (depicted in Figure 2): HRMS (electrospray ionization) calculated for C40H71N10O11 ([M + H]+) 867.5298; found: 867.5295. Subsequently, we prepared compound 8, which is the C-term carboxamide version of 5a. While the observed high proteolytic stability of cyclic peptides 5–8, especially 6–8, is consistent with the notion that cyclic peptides also tend to be more proteolytically stable than linear peptides [27], this also suggests that the cyclic peptide-based sirtuin substrates may also be useful in settings where native proteases/peptidases are present, such as cell lysates and intracellular compartments.

3. Experimental Section

3.1. General

The following materials were obtained from commercial sources for the compound synthesis and purification, and were used as received. Sigma-Aldrich China (Shanghai, China): N-methylmorpholine (NMM), trifluoroacetic acid (TFA), N,N-dimethylformamide (DMF), hydrazine monohydrate, Rink amide resin; TCI Shanghai (Shanghai, China): suberic acid, succinic acid, myristic acid; Alfa Aesar China (Shanghai, China): phenol, thioanisole, ethanedithiol, N-hydroxybenzotriazole (HOBt), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU); Honeywell China (Shanghai, China): acetonitrile, dichloromethane (DCM); Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China): piperidine, diethyl ether, acetic anhydride.
The Nα-Fmoc-protected amino acids were purchased from Sigma-Aldrich China, Alfa Aesar China, TCI Shanghai, or GL Biochem (Shanghai) Ltd. (Shanghai, China).
The high-resolution mass spectrometry (HRMS) was performed on an AB 5600+ Q TOF high-resolution mass spectrometer (AB Sciex LLC, Framingham, MA, USA) at the Pharmacy School of Fudan University. RP-HPLC analyses were performed on a Shimadzu LC-20AT station (Nakagyo-ku, Kyoto, Japan).
The following materials were obtained from commercial sources for the in vitro sirtuin deacylation activity assay and the pronase digestion assay, and were used as received. Sigma-Aldrich China: the active human recombinant His6-SIRT1, Trizma, Hepes, β-NAD+, a 1.0 M solution of MgCl2 (molecular-biology grade), the pronase from Streptomyces griseus; Cayman Chemical (Ann Arbor, MI, USA): the active human recombinant GST-SIRT1, the active human recombinant His6-SIRT2, the active human recombinant His6-SIRT3; TCI Shanghai: DL-dithiothreitol (DTT); Alfa Aesar China: NaCl, KCl.

3.2. Compound Preparation

The following describe the preparation of compounds 5–8, all starting from the Rink amide resin. The purified compounds 5–8 were obtained with overall yields of ~50–70%.

3.2.1. Preparation of Compounds 5 and 6 (Scheme 1)

A side-chain fully protected and N-terminus acetylated linear pentapeptide (i.e., CH3CONH-Lys(Mtt)-Lys(Boc)-(Nε-acetyl-Lysine)-Lys(Mtt)-Met) was initially assembled on the Rink amide resin (0.1 mmol) based on the Fmoc chemistry-based manual SPPS as follows. For each amino acid coupling, 4 equivalents of a Nα-Fmoc-protected amino acid, 3.8 equivalents of the coupling reagent HBTU, and 3.8 equivalents of the additive HOBt were used in the presence of 0.4 M NMM/DMF (2 mL), and the coupling reaction was allowed to proceed at room temperature for 1 h; A 20% (v/v) piperidine/DMF solution (5 mL) was used for Fmoc removal (10 min × 2). Subsequently, the side chain Mtt protecting group on Lys(Mtt) was selectively removed with a 1% (v/v) TFA/DMF solution (5 mL) (2 min × 9). The obtained peptidyl-resin with two exposed free amino groups was then divided into two equal portions and used for the synthesis of compounds 5 and 6 as follows. For the synthesis of 5, it was reacted with Fmoc-Gly-OH under amino acid coupling condition, followed by (i) Fmoc removal with 20% (v/v) piperidine/DMF (2.5 mL) (10 min × 2) and (ii) the subsequent reaction between the two newly exposed free amino groups on resin with suberic acid (0.1 mmol, 2 equivalents) in the presence of HBTU (0.19 mmol, 3.8 equivalents) and 0.4 M NMM/DMF (1 mL) at room temperature for 1 h. For the synthesis of 6, it was reacted with succinic acid (0.1 mmol, 2 equivalents) in the presence of HBTU (0.19 mmol, 3.8 equivalents) and 0.4 M NMM/DMF (1 mL) at room temperature for 1 h. The peptidyl resin obtained from the above-described reaction with a di-acid (suberic acid or succinic acid) was then treated with a TFA-containing solution (90% (v/v) TFA, 5% (v/v) DCM, 5% (v/v) ddH2O) (2.9 mL) at room temperature for 4 h to cleave 5 or 6 off the resin. Specifically, a cleavage mixture was filtered and the volatiles in the filtrate were removed with a stream of nitrogen gas in a well-ventilated fuming hood, and from the residue the crude 5 or 6 was precipitated out and washed with cold diethyl ether (2 mL and 2 × 2 mL, respectively). The obtained crude 5 and 6 were then purified by RP-HPLC on a semi-preparative C18 column (1 × 25 cm, 5 µm). The column was eluted with a gradient of ddH2O containing 0.05% (v/v) TFA and acetonitrile containing 0.05% (v/v) TFA at 4.5 mL/min and was monitored at 214 nm. The pooled desired HPLC fractions were concentrated with a rotary evaporator to remove acetonitrile and the remaining aqueous solutions were lyophilized to afford the purified 5 and 6 as puffy white solids. The exact masses of the purified 5 and 6 were confirmed by HRMS analysis (Table 1). The purities of the purified 5 and 6 were each >95% based on a RP-HPLC analysis on an analytical C18 column (0.46 × 25 cm, 5 μm).

3.2.2. Preparation of Compound 7 (Scheme 2)

A side-chain fully protected and N-terminus acetylated linear pentapeptide (i.e., CH3CONH-Lys(Mtt)-Arg(Pbf)-Lys(ivDde)-Lys(Mtt)-Thr(tBu)) was initially assembled on the Rink amide resin (0.05 mmol) based on the Fmoc chemistry-based manual SPPS, as described above. The two Mtt protecting groups on Lys(Mtt) were then selectively removed with 1% (v/v) TFA/DMF (2.5 mL) (2 min × 9). The resulting peptidyl-resin with two exposed free amino groups was then reacted with suberic acid (0.1 mmol, 2 equivalents) in the presence of HBTU (0.19 mmol, 3.8 equivalents) and 0.4 M NMM/DMF (1 mL) at room temperature for 1 h. The obtained peptidyl-resin was subsequently treated with a 2% (v/v) solution of hydrazine (NH2NH2) in DMF (5 mL) to selectively remove the ivDde protecting group on Lys(ivDde) (2 × 1 h at room temperature). The newly exposed free amino group was then reacted with myristic acid (0.2 mmol, 4 equivalents), HBTU (0.19 mmol, 3.8 equivalents), and HOBt (0.19 mmol, 3.8 equivalents) in the presence of 0.4 M NMM/DMF (1 mL). The peptidyl-resin thus obtained was subsequently treated with Reagent K (83.6% (v/v) TFA, 5.9% (v/v) phenol, 4.2% (v/v) ddH2O, 4.2% (v/v) thioanisole, 2.1% (v/v) ethanedithiol) (2.9 mL) at room temperature for 4 h to cleave 7 off the resin. Specifically, after a cleavage mixture was filtered and the volatiles in the filtrate were removed with a stream of nitrogen gas in a well-ventilated fuming hood, to the residue was added cold diethyl ether (2 mL and 2 × 2 mL, respectively) to precipitate out and wash the crude 7 which was then purified by RP-HPLC on a semi-preparative C18 column (1 × 25 cm, 5 µm), as described above, affording the purified 7 as a puffy white solid. The exact mass of the purified 7 was confirmed by HRMS analysis (Table 1). The purity of the purified 7 was >95% based on a RP-HPLC analysis on an analytical C18 column (0.46 × 25 cm, 5 μm).

3.2.3. Preparation of Compound 8 (Scheme 3)

Compound 8 was synthesized according to Scheme 3 in the same manner as the above-described synthesis of compound 5. The crude 8 was also purified with semi-preparative RP-HPLC and the exact mass of the purified 8 was also confirmed by HRMS analysis (Table 1). The purified 8 was also >95% pure based on RP-HPLC analysis.

3.3. Kinetic Parameter Determination for 5–8’s Substrate Activities with SIRT1/2/3

A sirtuin deacylation assay solution contained the following: 50 mM Hepes (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mM DTT, β-NAD+ (~5.6 × KM: 0.5 mM for the SIRT1 and SIRT2 assays, 3.5 mM for the SIRT3 assay), one test compound (5, 6, 7, or 8) with varied concentrations including 0, and a sirtuin (His6-SIRT1 or GST-SIRT1, 243 nM; His6-SIRT2, 297 nM; or His6-SIRT3, 739 nM). An enzymatic reaction was initiated by the addition of a sirtuin at 37 °C and was incubated at 37 °C for 5 min (for the SIRT1 assay) or 2 min (for the SIRT2 and SIRT3 assays) until quenched with the following stop solution: 100 mM HCl and 0.16 M acetic acid. The quenched assay solutions were directly injected into a C18 column (0.46 × 25 cm, 5 μm), and the column was eluted with a gradient of ddH2O containing 0.05% (v/v) TFA and acetonitrile containing 0.05% (v/v) TFA at 1 mL/min and was monitored at 214 nm. Turnover of the limiting substrate was kept at <10%. Stock solutions of the test compounds were all prepared in ddH2O. The integrated product and substrate HPLC peak areas were then used to determine the initial velocities for the sirtuin-catalyzed deacylation reaction at different concentrations of a test compound (5, 6, 7, or 8). The initial velocity-concentration data were analyzed with KaleidaGraph® (Synergy Software, Reading, PA, USA) and the data were fitted to the Michaelis-Menten equation to obtain the kinetic parameters kcat and KM, as recorded in Table 2 and Table 3. Of note, non-enzymatic control runs did not yield deacylation product even when the highest concentration of a test compound (i.e., 5, 6, 7, or 8) was used.

3.4. Pronase Digestion Assay

This assay was performed according to the procedure described previously by our laboratory [35]. A solution of a test compound (5, 6, 7, or H2N-HK-(Nε-acetyl-lysine)-LM-COOH) in ddH2O (160 µM) was mixed with equal volume of a pronase solution in 100 mM Tris HCl (pH 7.3) (8 ng/µL); the resulting well-mixed solution was then incubated at 37 °C until quenched with a 1.0 M solution of acetic acid in ddH2O at 0, 7.5, 15, 30, and 60 min (for 5, 6, and 7) or 0, 1.5, 3, and 6 min (for H2N-HK-(Nε-acetyl-lysine)-LM-COOH). At each time point, 20 µL of a pronase digestion solution was taken and treated with 40 µL of the 1.0 M acetic acid aqueous solution; and the whole mixture was vortexed vigorously, centrifuged, and the supernatant was injected into a RP-HPLC analytical C18 column (0.46 × 25 cm, 5 μm). The column was eluted with a gradient of ddH2O containing 0.05% (v/v) TFA and acetonitrile containing 0.05% (v/v) TFA at 1 mL/min with ultraviolet monitoring at 214 nm. The HPLC peak areas for a given test compound at different time points were used to estimate the percentage remaining for this test compound versus digestion time. The graph of the percentage remaining versus digestion time was used to compare the proteolytic stability of different test compounds, as shown in Figure 4.

4. Conclusions

In the current study, we found that several cyclic peptides harboring Nε-acetyl-lysine or Nε-myristoyl-lysine behaved as superior in vitro SIRT1 or SIRT3 substrates (as judged by the kcat/KM ratios) compared to the best linear hexapeptide-based in vitro SIRT1 or SIRT3 substrates reported in the current literature. Moreover, these cyclic peptides were also found to be proteolytically much more stable than a linear pentapeptide control. These cyclic peptide-based substrates may be also useful in in vitro screening platforms for sirtuin chemical modulator discovery; if cell permeable, they may also be used to assess intracellular sirtuin deacylation activities when combined with the use of the potent/selective/cell permeable sirtuin deacylation inhibitors.

Author Contributions

W.Z.: conceived and designed the study, designed experiments, analyzed experimental data, wrote the manuscript; D.C. and L.Y.: designed and implemented experiments, acquired and analyzed experimental data.

Funding

This research was funded by the National Natural Science Foundation of China, grant number 21272094 and The APC was also funded by this grant.

Acknowledgments

We would like to thank the following for their financial supports to this work: the National Natural Science Foundation of China (grant no. 21272094), the Jiangsu provincial specially appointed professorship, and the Jiangsu provincial “innovation and venture talents” award plan.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Greiss, S.; Gartner, A. Sirtuin/Sir2 phylogeny, evolutionary considerations and structural conservation. Mol. Cells 2009, 28, 407–415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Li, Y.; Zhou, Y.; Wang, F.; Chen, X.; Wang, C.; Wang, J.; Liu, T.; Li, Y.; He, B. SIRT4 is the last puzzle of mitochondrial sirtuins. Bioorg. Med. Chem. 2018, 26, 3861–3865. [Google Scholar] [PubMed]
  3. Hu, X.; Zheng, W. Chemical probes in sirtuin research. In Progress in Molecular Biology and Translational Science. Sirtuins in Health and Disease, 1st ed.; Zheng, W., Ed.; Academic Press: Cambridge, MA, USA, 2018; Volume 154, pp. 1–24. [Google Scholar]
  4. Rajabi, N.; Galleano, I.; Madsen, A.S.; Olsen, C.A. Targeting sirtuins: Substrate specificity and inhibitor design. In Progress in Molecular Biology and Translational Science. Sirtuins in Health and Disease, 1st ed.; Zheng, W., Ed.; Academic Press: Cambridge, MA, USA, 2018; Volume 154, pp. 25–69. [Google Scholar]
  5. Li, S.; Zheng, W. Mammalian sirtuins SIRT4 and SIRT7. In Progress in Molecular Biology and Translational Science. Sirtuins in Health and Disease, 1st ed.; Zheng, W., Ed.; Academic Press: Cambridge, MA, USA, 2018; Volume 154, pp. 147–168. [Google Scholar]
  6. Bheda, P.; Jing, H.; Wolberger, C.; Lin, H. The substrate specificity of sirtuins. Annu. Rev. Biochem. 2016, 85, 405–429. [Google Scholar] [CrossRef] [PubMed]
  7. Chen, B.; Zang, W.; Wang, J.; Huang, Y.; He, Y.; Yan, L.; Liu, J.; Zheng, W. The chemical biology of sirtuins. Chem. Soc. Rev. 2015, 44, 5246–5264. [Google Scholar] [CrossRef] [PubMed]
  8. Martínez-Redondo, P.; Vaquero, A. The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer 2013, 4, 148–163. [Google Scholar] [CrossRef] [PubMed]
  9. Kumar, S.; Lombard, D.B. Functions of the sirtuin deacylase SIRT5 in normal physiology and pathobiology. Crit. Rev. Biochem. Mol. Biol. 2018, 53, 311–334. [Google Scholar] [CrossRef] [PubMed]
  10. Elkhwanky, M.S.; Hakkola, J. Extranuclear sirtuins and metabolic stress. Antioxid. Redox. Signal. 2018, 28, 662–676. [Google Scholar] [CrossRef] [PubMed]
  11. Bringman-Rodenbarger, L.R.; Guo, A.H.; Lyssiotis, C.A.; Lombard, D.B. Emerging roles for SIRT5 in metabolism and cancer. Antioxid. Redox. Signal. 2018, 28, 677–690. [Google Scholar] [CrossRef]
  12. Sebastián, C.; Mostoslavsky, R. The role of mammalian sirtuins in cancer metabolism. Semin. Cell Dev. Biol. 2015, 43, 33–42. [Google Scholar] [CrossRef]
  13. Choi, J.E.; Mostoslavsky, R. Sirtuins, metabolism, and DNA repair. Curr. Opin. Genet. Dev. 2014, 26, 24–32. [Google Scholar] [CrossRef] [Green Version]
  14. Dai, Y.; Faller, D.V. Transcription regulation by class III histone deacetylases (HDACs)-sirtuins. Transl. Oncogenomics 2008, 3, 53–65. [Google Scholar] [PubMed]
  15. Wang, Y.; He, J.; Liao, M.; Hu, M.; Li, W.; Ouyang, H.; Wang, X.; Ye, T.; Zhang, Y.; Ouyang, L. An overview of sirtuins as potential therapeutic target: Structure, function and modulators. Eur. J. Med. Chem. 2019, 161, 48–77. [Google Scholar] [CrossRef] [PubMed]
  16. Neo, S.H.; Tang, B.L. Sirtuins as modifiers of huntington’s disease (HD) pathology. In Progress in Molecular Biology and Translational Science. Sirtuins in Health and Disease, 1st ed.; Zheng, W., Ed.; Academic Press: Cambridge, MA, USA, 2018; Volume 154, pp. 105–145. [Google Scholar]
  17. Schiedel, M.; Robaa, D.; Rumpf, T.; Sippl, W.; Jung, M. The current state of NAD+-dependent histone deacetylases (sirtuins) as novel therapeutic targets. Med. Res. Rev. 2018, 38, 147–200. [Google Scholar] [CrossRef] [PubMed]
  18. Jiang, Y.; Liu, J.; Chen, D.; Yan, L.; Zheng, W. Sirtuin inhibition: Strategies, inhibitors, and therapeutic potential. Trends Pharmacol. Sci. 2017, 38, 459–472. [Google Scholar] [CrossRef] [PubMed]
  19. Dai, H.; Sinclair, D.A.; Ellis, J.L.; Steegborn, C. Sirtuin activators and inhibitors: Promises, achievements, and challenges. Pharmacol. Ther. 2018, 188, 140–154. [Google Scholar] [CrossRef] [PubMed]
  20. Hong, J.Y.; Zhang, X.; Lin, H. HPLC-based enzyme assays for sirtuins. Methods Mol. Biol. 2018, 1813, 225–234. [Google Scholar] [PubMed]
  21. Galleano, I.; Schiedel, M.; Jung, M.; Madsen, A.S.; Olsen, C.A. A continuous, fluorogenic sirtuin 2 deacylase assay: Substrate screening and inhibitor evaluation. J. Med. Chem. 2016, 59, 1021–1031. [Google Scholar] [CrossRef]
  22. Chiang, Y.L.; Lin, H. An improved fluorogenic assay for SIRT1, SIRT2, and SIRT3. Org. Biomol. Chem. 2016, 14, 2186–2190. [Google Scholar] [CrossRef] [Green Version]
  23. Schuster, S.; Roessler, C.; Meleshin, M.; Zimmermann, P.; Simic, Z.; Kambach, C.; Schiene-Fischer, C.; Steegborn, C.; Hottiger, M.O.; Schutkowski, M. A continuous sirtuin activity assay without any coupling to enzymatic or chemical reactions. Sci. Rep. 2016, 6. [Google Scholar] [CrossRef]
  24. Li, Y.; Liu, T.; Liao, S.; Li, Y.; Lan, Y.; Wang, A.; Wang, Y.; He, B. A mini-review on sirtuin activity assays. Biochem. Biophys. Res. Commun. 2015, 467, 459–466. [Google Scholar] [CrossRef]
  25. Roessler, C.; Tüting, C.; Meleshin, M.; Steegborn, C.; Schutkowski, M. A novel continuous assay for the deacylase sirtuin 5 and other deacetylases. J. Med. Chem. 2015, 58, 7217–7223. [Google Scholar] [CrossRef] [PubMed]
  26. Teng, Y.B.; Jing, H.; Aramsangtienchai, P.; He, B.; Khan, S.; Hu, J.; Lin, H.; Hao, Q. Efficient demyristoylase activity of SIRT2 revealed by kinetic and structural studies. Sci. Rep. 2015, 5. [Google Scholar] [CrossRef] [PubMed]
  27. Goodman, M.; Ro, S. Peptidomimetics for drug design. In Burger’s Medicinal Chemistry and Drug Discovery. Principles and Practice, 5th ed.; Wolff, M.E., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 1995; Volume 1, pp. 803–861. [Google Scholar]
  28. Huang, Y.; Liu, J.; Yan, L.; Zheng, W. Simple Nε-thioacetyl-lysine-containing cyclic peptides exhibiting highly potent sirtuin inhibition. Bioorg. Med. Chem. Lett. 2016, 26, 1612–1617. [Google Scholar] [CrossRef] [PubMed]
  29. Fatkins, D.G.; Monnot, A.D.; Zheng, W. Nε-thioacetyl-lysine: A multi-facet functional probe for enzymatic protein lysine Nε-deacetylation. Bioorg. Med. Chem. Lett. 2006, 16, 3651–3656. [Google Scholar] [CrossRef] [PubMed]
  30. Smith, B.C.; Denu, J.M. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. Biochemistry 2007, 46, 14478–14486. [Google Scholar] [CrossRef]
  31. Feldman, J.L.; Baeza, J.; Denu, J.M. Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J. Biol. Chem. 2013, 288, 31350–31356. [Google Scholar] [CrossRef] [PubMed]
  32. Liu, J.; Zheng, W. Cyclic peptide-based potent human SIRT6 inhibitors. Org. Biomol. Chem. 2016, 14, 5928–5935. [Google Scholar] [CrossRef] [PubMed]
  33. Hirsch, B.M.; Hao, Y.; Li, X.; Wesdemiotis, C.; Wang, Z.; Zheng, W. A mechanism-based potent sirtuin inhibitor containing Nε-thiocarbamoyl-lysine (TuAcK). Bioorg. Med. Chem. Lett. 2011, 21, 4753–4757. [Google Scholar] [CrossRef] [PubMed]
  34. Roche Applied Science. Pronase: Product Description. Available online: https://www.sigmaaldrich.com/catalog/product/roche/pronro?lang=en&region=SX (accessed on 19 January 2019).
  35. Hirsch, B.M.; Gallo, C.A.; Du, Z.; Wang, Z.; Zheng, W. Discovery of potent, proteolytically stable, and cell permeable human sirtuin peptidomimetic inhibitors containing Nε-thioacetyl-lysine. Med. Chem. Comm. 2010, 1, 233–238. [Google Scholar] [CrossRef]
Molecules 24 00424 g001 550
Figure 1. The sirtuin-catalyzed β-NAD+-dependent deacylation of protein-based or peptide-based Nε-acyl-lysine substrates. Example R groups of R-C(=O)- removable by different human sirtuins are shown in the box. The two asterisks in the box denote that the SIRT7-catalyzed deacetylation and demyristoylation become appreciable only in the presence of dsDNA, rRNA, or tRNA.
Figure 1. The sirtuin-catalyzed β-NAD+-dependent deacylation of protein-based or peptide-based Nε-acyl-lysine substrates. Example R groups of R-C(=O)- removable by different human sirtuins are shown in the box. The two asterisks in the box denote that the SIRT7-catalyzed deacetylation and demyristoylation become appreciable only in the presence of dsDNA, rRNA, or tRNA.
Molecules 24 00424 g001
Molecules 24 00424 g002 550
Figure 2. Notable examples of the currently existing in vitro SIRT1/2/3 substrates. Note: (i) the kcat/KM values for the SIRT1/2/3-catalyzed deacylation of these substrates are shown in the parenthesis below each chemical structure. (ii) The sequence of peptides 1 and 2 was derived from tumor suppressor protein p53, and that of peptides 3 and 4 was derived from the tumor necrosis factor α (TNFα).
Figure 2. Notable examples of the currently existing in vitro SIRT1/2/3 substrates. Note: (i) the kcat/KM values for the SIRT1/2/3-catalyzed deacylation of these substrates are shown in the parenthesis below each chemical structure. (ii) The sequence of peptides 1 and 2 was derived from tumor suppressor protein p53, and that of peptides 3 and 4 was derived from the tumor necrosis factor α (TNFα).
Molecules 24 00424 g002
Molecules 24 00424 g003 550
Figure 3. The design of compounds 5–8.
Figure 3. The design of compounds 5–8.
Molecules 24 00424 g003
Molecules 24 00424 sch001 550
Scheme 1. The synthetic scheme of compounds 5 and 6.
Scheme 1. The synthetic scheme of compounds 5 and 6.
Molecules 24 00424 sch001
Molecules 24 00424 sch002 550
Scheme 2. The synthetic scheme of compound 7.
Scheme 2. The synthetic scheme of compound 7.
Molecules 24 00424 sch002
Molecules 24 00424 sch003 550
Scheme 3. The synthetic scheme of compound 8.
Scheme 3. The synthetic scheme of compound 8.
Molecules 24 00424 sch003
Molecules 24 00424 g004 550
Figure 4. The pronase digestion profiles of compounds 5 (■), 6 (●), 7 (♦), and the linear pentapeptide H2N-HK-(Nε-acetyl-lysine)-LM-COOH (▲). Note: The linear pentapeptide H2N-HK-(Nε-acetyl-lysine)-LM-COOH has been used extensively in our laboratory as a control of the pronase digestion assay.
Figure 4. The pronase digestion profiles of compounds 5 (■), 6 (●), 7 (♦), and the linear pentapeptide H2N-HK-(Nε-acetyl-lysine)-LM-COOH (▲). Note: The linear pentapeptide H2N-HK-(Nε-acetyl-lysine)-LM-COOH has been used extensively in our laboratory as a control of the pronase digestion assay.
Molecules 24 00424 g004
Table
Table 1. The high-resolution mass spectrometry (HRMS) analysis of the purified compounds 5–8 a.
Table 1. The high-resolution mass spectrometry (HRMS) analysis of the purified compounds 5–8 a.
CompoundIonic FormulaCalculated m/zObserved m/z
5[C45H81N12O11S]+997.5863997.5856
6[C37H67N10O9S]+827.4808827.4778
7[C52H97N12O10]+1049.74451049.7449
8[C40H71N11O10Na]+888.5278888.5282
a All compounds were measured with electrospray ionization (positive ion mode).
Table
Table 2. The kinetic parameters for compounds 5/6’s substrate activities with SIRT1/2/3 a.
Table 2. The kinetic parameters for compounds 5/6’s substrate activities with SIRT1/2/3 a.
Compound56
SirtuinKM (μM)kcat (10−3, s−1)kcat/KM (M−1·s−1)KM (μM)kcat (10−3, s−1)kcat/KM (M−1·s−1)
SIRT122.2 ± 1.835.6 ± 5.1(1.6 ± 0.1) × 10341.3 ± 1.8325.9 ± 2.3(0.63 ± 0.03) × 103
SIRT211.6 ± 2.236.0 ± 4.9(3.2 ± 1.0) × 10349.7 ± 7.78138.9 ± 26.7(2.79 ± 0.1) × 103
SIRT34.5 ± 0.915.8 ± 1.4(3.6 ± 0.4) × 10334.9 ± 4.04155.3 ± 16.6(4.51 ± 1.0) × 103
a See Experimental Section for assay details.
Table
Table 3. The kinetic parameters for compounds 7/8’s substrate activities with SIRT1/2/3 a.
Table 3. The kinetic parameters for compounds 7/8’s substrate activities with SIRT1/2/3 a.
Compound78
SirtuinKM (μM)kcat (10−3, s−1)kcat/KM (M−1·s−1)KM (μM)kcat (10−3, s−1)kcat/KM (M−1·s−1)
SIRT12.85 ± 0.135.8 ± 0.1(2.04 ± 0.06) × 10342.2 ± 17.590.2 ± 39.4(2.2 ± 0.05) × 103
SIRT237.6 ± 14.490.9 ± 2.62(2.6 ± 0.93) × 10343.1 ± 16.0414.0 ± 25.0(10.4 ± 4.4) × 103
SIRT34.2 ± 0.3860.0 ± 2.8(14.3 ± 0.66) × 10399.9 ± 48.7221.0 ± 32.0(2.4 ± 0.9) × 103
a See Experimental Section for assay details.

Share and Cite

MDPI and ACS Style

Chen, D.; Yan, L.; Zheng, W. Cyclic Peptide-Based Sirtuin Substrates. Molecules 2019, 24, 424. https://doi.org/10.3390/molecules24030424

AMA Style

Chen D, Yan L, Zheng W. Cyclic Peptide-Based Sirtuin Substrates. Molecules. 2019; 24(3):424. https://doi.org/10.3390/molecules24030424

Chicago/Turabian Style

Chen, Di, Lingling Yan, and Weiping Zheng. 2019. "Cyclic Peptide-Based Sirtuin Substrates" Molecules 24, no. 3: 424. https://doi.org/10.3390/molecules24030424

Article Metrics

Back to TopTop